News

VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement.

Novartis announced today that the European Commission (EC) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive,

Duality Biologics a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate therapeutics today announced the expansion of its ongoing collaboration with Adcendo ApS ("Adcendo")

Shorla Oncology, a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers.

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference

Roche announced today the U.S. Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC) for the PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* test.

Nanjing Leads Biolabs Co., Ltd. announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global intellectual property rights for the treatment of neuroendocrine cancer, has obtained Orphan Drug Designation

Lepu Biopharma Co., Ltd. and Beijing DP Tech Co., Ltd. (DP Technology) have recently announced a significant milestone in their Antibody-Drug Conjugate (ADC) drug collaboration. This partnership has effectively integrated DP's ADC Linker

Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic collaboration with Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies.

Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced they have entered into a global strategic collaboration to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor, being investigated for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.